Information about ALS TDI’s subsidiary, Anelixis Therapeutics

Below is information that explains ALS TDI’s relationship with Anelixis Therapeutics. Every decision ALS TDI has made, and continues to make, is to achieve our mission: to discover and develop effective treatments to end ALS as soon as possible for patients today.

What is Anelixis Therapeutics?
Anelixis Therapeutics, LLC, is a mission-aligned translational medicine and drug development company created and wholly-owned by the ALS Therapy Development Institute.

Why did TDI create Anelixis?
TDI created Anelixis to have access to additional funding from venture capitalists, angel investors, etc. to move promising potential treatments for ALS from preclinical studies at ALS TDI into clinical trials.

Why is Anelixis needed?
There is currently no effective treatment for ALS. On average, it takes 15 years and at least $2 billion to bring a new therapy to patients – too long and too expensive for ALS patients today. Anelixis is one important piece of solving this problem.

Anelixis was created to bridge the gap between preclinical validation and clinical trial, specifically to raise and spend funds on IND-enabling studies for early Phase I/II clinical trials. This data is becoming more and more necessary for further investment from pharmaceutical companies which can take these potential treatments through Phase III and onto the market. Licensing drugs from TDI and other like-minded organizations, Anelixis uses innovative business models as a virtual biotech to advance potential ALS treatments.

Does my donation to TDI go to Anelixis?
No. Every dollar donated goes to ALS TDI, not to Anelixis. Anelixis will not be funded by patients and families.

For more information, questions and inquiries, please visit the website for Anelixis at www.anelixistherapeutics.com or contact 617-599-6514.